Drug challenge in Brugada syndrome – Cardiology MCQ – Answer Which of the following is not usually used as drug challenge to unmask the Brugada Type I ECG
Genetic basis in Brugada Syndrome – Cardiology MCQ Genetic basis in Brugada Syndrome has been identified in — percentage of cases currently: a) 30% b) 50% c) 70%
Drug challenge in Brugada syndrome – Cardiology MCQ Which of the following is not usually used as drug challenge to unmask the Brugada Type I ECG pattern? a)
Mortality in hypertrophic cardiomyopathy – Cardiology MCQ – Answer Disease specific mortality in hypertrophic cardiomyopathy – Correct answer: a) 0.5% per year Hypertrophic cardiomyopathy (HCM) is the commonest among
Desmopressin – Cardiology MCQ – Answer Which of the following is not an adverse effect of desmopressin used in the treatment of postural hypotension? – Correct answer: d)
Mortality in hypertrophic cardiomyopathy – Cardiology MCQ Disease specific mortality in hypertrophic cardiomyopathy: a) 0.5% per year b) 5% per year c) 10 % per year d) 15%
Desmopressin – Cardiology MCQ Which of the following is not an adverse effect of desmopressin used in the treatment of postural hypotension? a) Water intoxication b) Hyponatremia c)
Side effects of fludrocortisone – Cardiology MCQ – Answer Side effects of fludrocortisone does not include – Correct answer: d) Postural hypotension Fludrocortisone is an important drug for
DOAC in renal impairment – Cardiology MCQ – Answer Which of the following direct oral anticoagulants (DOACs) is most suitable in a patient with atrial fibrillation and renal
Benefit of DOAC over warfarin – Cardiology MCQ – Answer Which of the following is NOT a known advantage of direct oral anticoagulant (DOAC) over warfarin? – Correct